author-photo

Ching Yuan Kuo

Memorial Hospital of South Bend

20

Papers

126

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia: Chronic Lymphocytic Leukaemia in Taiwan

2019 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (2)
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

2019 Lancet Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (69)
NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Risk Factors Associated with Earlier Relapse and Death and Treatment Response in Patients with Follicular Lymphoma in Taiwan

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study

2017 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (1)
Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)
High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Molecular Responses at 3 and 6 Months Predict Outcomes in Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Front-line Imatinib: Taiwan CML Study Group

2014 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Pegylated arginine deiminase (ADI-PEG20) in relapsed/refractory and/or elder Acute Myeloid Leukemia: The preliminary result of phase II trial

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)
No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)